What to Expect From Oracle Earnings This Week
Oracle is expected to release its fiscal first-quarter financial results on this coming Thursday.
All Work
Chris Lange
Why Analysts Are Chasing Finisar Targets Up So Much
Finisar kicked off its fiscal year with a solid beat in the first quarter, and it is looking to continue to beat in the second.
5 Companies That Destroyed Shareholders Last Week
There are a fair number of questions for what the markets hold after this summer, but a somewhat negative analyst sentiment surrounds Friday's move lower.
Restoration Hardware Earnings Overcome Near-Term Weakness
Restoration Hardware admitted to short-term weakness in the future that some would think should send the shares lower. However this was not the case.
Why Lexicon Pharma Is Soaring
Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.
Why a Kroger Earnings Beat Is Not Enough for Investors
Kroger reported mixed fiscal second-quarter financial results and lowered its guidance before the markets opened Friday.
Why Repros Is Rising
Shares of Repros Therapeutics climbed in Thursday’s session after the company announced results from its mid-stage study for women with moderate to severe confirmed endometriosis.
What Analysts Are Saying About Apple After the iPhone 7 Debut
Practically everyone had an opinion on the new iPhone 7, as well as where Apple and the iPhone family stand to go from here.
What to Expect From Kroger Earnings
Kroger is scheduled to release its fiscal second-quarter earnings report before the markets open on Friday.
Honeywell Plans Spin-Off Dividend for Early October
Honeywell International took another step in its evolution when it announced that its board of directors has declared a pro rata dividend of AdvanSix common stock.
Is Pier 1 Losing Its Best Shot at a Turnaround?
Pier 1 Imports gave a business update after the markets closed on Wednesday, revising its preliminary results and guidance and announcing a transition in management.
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
HPE Earnings Report Overshadowed By Spin-Off Merger
Hewlett Packard Enterprise Co. (NYSE: HPE) reported its fiscal third-quarter financial results after markets closed on Wednesday. However these earnings were overshadowed by the company’s most recent spin-off and merger. The company said that…
Did Agios Just Speed Up Its Business Plan by 2 Years?
Celgene is making a move out of left field that has sent shares of its partner Agios Pharmaceuticals significantly higher.
Is the FDA Changing Its Tune on Evoke Pharma?
Evoke Pharma shares saw a handy gain on Wednesday following news of a positive meeting with the FDA over Gimoti.
What to Expect From Hewlett Packard Enterprise Earnings
Hewlett Packard Enterprise is scheduled to report its fiscal third-quarter financial results after the markets close on Wednesday.
Is the Western Digital Turnaround for Real This Time?
Western Digital has been on the slide for the past couple of years, but Wednesday morning offered a shot of life for the company.
Why Retrophin Shares Have Soared
Shares of Retrophin climbed early on Wednesday following positive top-line news from its mid-stage trial for the treatment of focal segmental glomerulosclerosis.
Top 5 Earnings for the Coming Week
24/7 Wall St. has put together a preview of Hewlett Packard Enterprise and some of the other notable companies reporting in the coming week.
5 Speculative Biotech Analyst Stocks Under $10 With Massive Upside
What most investors are looking for is a solid solution in what is a confusing market. So we have compiled a list of a few biotech companies that fit the bill, and analysts are…